)
Visual
test
Immix Biopharma
Immix Biopharma (IMMX) investor relations material
Immix Biopharma Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary25 Mar, 2026
Executive summary
Clinical-stage biopharma focused on CAR-T therapies for AL Amyloidosis and other serious diseases, with lead candidate NXC-201 in Phase 1b/2 trials in the US and ex-US.
NXC-201 received FDA Breakthrough Therapy, RMAT, and Orphan Drug Designations, and EU Orphan Drug Designation.
Positive interim Phase 2 data: 75% complete response rate in relapsed/refractory AL Amyloidosis, no neurotoxicity observed.
Raised $100M in December 2025 public offering and $9.3M in September 2025 private placement.
Financial highlights
Net loss for 2025: $29.4M, up from $21.7M in 2024.
Research and development expenses: $16.3M in 2025, up from $11.3M in 2024.
General and administrative expenses: $13.7M in 2025, up from $11.4M in 2024.
Cash, cash equivalents, and short-term investments: $100.4M as of Dec 31, 2025.
Working capital: $91.1M as of Dec 31, 2025.
Outlook and guidance
Cash runway expected to fund operations for at least 12 months from report date; additional capital will be needed for long-term operations and commercialization.
Final NXC-201 trial readout and BLA submission planned after completion of ongoing Phase 1b/2 trial.
Ongoing expansion of clinical trial sites and pipeline development.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Immix Biopharma
- NXC-201 delivers 75% complete response in relapsed/refractory AL amyloidosis, redefining outcomes.IMMX
Corporate presentation16 Mar 2026 - Registering up to $750M in securities to advance CAR-T therapy NXC-201 for rare diseases.IMMXRegistration Filing9 Jan 2026
- Resale registration after $9.3M PIPE may add volatility; warrant proceeds to fund operations.IMMXRegistration Filing16 Dec 2025
- Annual meeting to elect eight directors and ratify Crowe LLP as auditor; board is majority independent.IMMXProxy Filing2 Dec 2025
- Shareholders will vote on eight directors and auditor ratification at the June 2025 meeting.IMMXProxy Filing2 Dec 2025
- New clawback policy mandates recovery of executive pay after restatements, regardless of fault.IMMXProxy Filing2 Dec 2025
- NXC-201 achieved a 70% CR rate with rapid, durable responses and no neurotoxicity.IMMXStatus Update18 Nov 2025
- Net loss rose to $7.6M in Q3 2025 as clinical progress continued, with cash at $15.9M.IMMXQ3 20257 Nov 2025
- Net loss widened on higher R&D, with cash runway concerns despite clinical and grant milestones.IMMXQ2 20258 Aug 2025
Next Immix Biopharma earnings date
Q1 20266 May, 2026
Immix Biopharma
Next Immix Biopharma earnings date
Q1 20266 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage